May 2026 brought a wave of psychiatry data that challenges some long-held assumptions about how and where mental health treatment gets delivered. The 6-week transcranial magnetic stimulation (TMS) schedule is no longer the only option or even the standard one for some patients. A conversational AI platform outperformed group therapy for anxiety in a controlled trial. New mechanistic research is beginning to explain not just that TMS works but how it works at the circuit level.
Rounding out the month, a network meta-analysis gave clinicians rare comparative data on adjunctive antipsychotics for major depressive disorder (MDD), and emerging precision psychiatry research raised an intriguing question: could monocyte epigenetic aging help identify biologically distinct depression subtypes?
Here are the 5 stories worth catching up on before June gets any further.
Accelerated & At-Home TMS: What the Latest Data Mean for MDD Practice
TMS for MDD is rapidly evolving beyond its traditional 36-session, 6-week schedule. A retrospective analysis found that 5x5 accelerated rTMS—5 sessions per day over 5 consecutive days—produced comparable PHQ-9 reductions to conventional treatment, with delayed improvement emerging 2 to 4 weeks post-course. The SWIFT accelerated deep TMS protocol similarly demonstrated faster week-2 symptom reduction versus standard high-frequency stimulation. In January 2026, the US Food & Drug Administration (FDA) approved ProlivRx, the first prescription at-home brain neuromodulation therapy for MDD, shown in the MOOD trial to achieve significantly greater remission rates versus sham (21.3% vs 6.0%).
Scott Wilke, MD, of UCLA Health, discussed how accelerated TMS protocols are reshaping depression care and what new preclinical findings published in Cell suggest about the mechanism behind transcranial magnetic stimulation's antidepressant effects. Rather than broadly activating the brain, accelerated intermittent theta-burst stimulation (aiTBS) appears to selectively restore stress-disrupted circuitry in distinct neural cell types—a finding that could eventually support more personalized, circuit-targeted neuromodulation strategies. Wilke emphasized that TMS is no longer experimental, calling it the best next step for treatment-resistant depression after antidepressant failure, while noting insurance coverage for accelerated protocols remains a significant barrier to access.
Conversational AI in Mental Health: RCT Data Raises the Bar
A randomized controlled trial of 995 university students found that a conversational AI intervention (Kai.ai) reduced anxiety more than group therapy and a waiting list control at 12 weeks, with 57.9% of participants with clinical anxiety at baseline remitting to nonclinical levels versus 14.4% with group therapy. Depression outcomes were comparable between AI and group therapy; PTSD symptoms did not improve, highlighting limits of AI-based care for trauma.
Investigator Anat Shoshani, PhD, of Reichman University, emphasized that digital therapeutic alliance drove engagement and outcomes, framing conversational AI not as a therapy replacement but as a tool for continuous mental health support between and beyond formal clinical care.
Related: Your Patient's New Therapist Is an AI. Now What?
Adjunctive MDD Therapies and Precision Psychiatry: What Caught Our Attention in May
A network meta-analysis presented at the 2026 NEI Spring Congress found lumateperone (CAPLYTA) demonstrated the largest effect size across 4 key efficacy outcomes—MADRS change from baseline, response, remission, and CGI-S change—when indirectly compared with aripiprazole, brexpiprazole, cariprazine, and quetiapine XR as adjunctive therapies for major depressive disorder (MDD). Lumateperone also showed no clinically significant weight gain versus placebo and was the only agent comparable to placebo for akathisia risk.
Leslie Citrome, MD, of New York Medical College emphasized that in the absence of head-to-head trials, network meta-analyses provide clinicians the best available comparative context for adjunctive atypical antipsychotic selection in MDD.
Related: Need for Head-to-Head Adjunctive MDD Data, With Leslie Citrome, MD
Data from the Women's Interagency HIV Study (WIHS) suggest monocyte-specific epigenetic age acceleration (EAA) may help distinguish biologically distinct depression subtypes, particularly those characterized by non-somatic symptoms. Among 440 participants, monocyte EAA was significantly associated with non-somatic depressive symptoms (P =.018), with the strongest signals for anhedonia (P = .007) and hopelessness (P =.007). No associations were found for somatic symptoms, and a multi-tissue Horvath clock showed no significant associations.
Nicole Beaulieu Perez, PhD, of NYU Rory Meyers College of Nursing, emphasized the findings are not yet clinically actionable, noting replication studies and greater understanding of epigenetic mark malleability are needed before monocyte EAA could inform precision psychiatry practice.
Related:
Monocyte Aging Links to Non-Somatic Depression Symptoms, With Nicole Perez, PhD
Monocyte Clock Detects Depression Signals, With Nicole Perez, PhD
